The EPS miss is minor and offset by improved cash position and regulatory progress. The key catalyst is initial clinical data expected in 2026, monitor for presentation date. No immediate trading trigger; stock likely range-bound until data readout.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · May 13 $3.06entry
- T+1 · 6mo ago 0.00%α +0.00% · $3.06
- T+5 · 6mo ago −12.42%α −11.26% · $2.68
- T+20 · 5mo ago −9.80%α −9.19% · $2.76
- T+60 · due 3mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Nkarta reported Q1 2026 EPS of -$0.37, a slight miss vs consensus of -$0.36, with no revenue. The company highlighted FDA agreement for outpatient dosing and expansion into rheumatoid arthritis, with initial clinical data expected in 2026. Cash runway into 2029 provides stability, but the EPS miss and lack of near-term catalysts keep sentiment neutral.
Key Financial Metrics
Key Facts
- Q1 2026 EPS: -$0.37 vs consensus -$0.36 (miss of 2.8%)
- No revenue reported (pre-revenue biotech)
- Cash balance: $266.7M as of March 31, 2026, expected to fund operations into 2029
- Net loss: $27.8M for Q1 2026, improved from $32.0M in Q1 2025
- FDA agreement to allow outpatient dosing, re-dosing, and expansion into rheumatoid arthritis
- Initial clinical data from Ntrust-1 and Ntrust-2 expected at a medical conference in 2026
Financial Impact
EPS miss of $0.01 vs consensus; net loss improved by $4.2M YoY; cash burn of ~$28.4M in Q1
Risk Factors
- Clinical trial failure or disappointing data
- Dilution risk if cash runway shortens
- Regulatory setbacks despite recent FDA agreement
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293350 |
Track record
13 reports on NKTX
5 of 9 bullish or bearish reports moved the stock their way by T+1. Best: +31.21% at T+5 after the Nov 5, 2026 report. 7 of 9 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
- Nov 9, 20267d ago Press Release Bullish 7/10 Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
- Nov 6, 202610d ago 8-K Neutral 3/10 Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Bearish 5/10 Entry $1.73 to $1.59 Now $1.21 +30.06% ▲ +8.09% +10.46% vs SPY
- Aug 10, 202614w ago 8-K Bearish 6/10 Entry $2.33 to $2.39 Now $1.21 +48.07% ▼ −2.58% −2.32% vs SPY
- May 12, 202626w ago Press Release Neutral 4/10 Viewing Entry $3.06 to $3.06 Now $1.21 −60.46% · 0.00% +0.00% vs SPY
- Apr 15, 202630w ago Press Release Bullish 7/10 Entry $2.80 to $3.47 Now $1.21 −56.79% ▲ +23.93% +22.71% vs SPY
- Apr 6, 202632w ago EFFECT Bearish 7/10 Entry $2.36 to $2.25 Now $1.21 +48.73% ▲ +4.66% +4.72% vs SPY
- Mar 25, 202633w ago 8-K Bearish 6/10 Entry $2.14 to $2.06 Now $1.21 +43.46% ▲ +3.74% +2.06% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers